Association of TNF2, a TNF-α promoter polymorphism, with septic shock susceptibility and mortality: A multicenter study

JAMA

Volumn 282, Issue 6, 1999, Pages 561-568

  Mira, Jean Paul ^a   Cariou, Alain ^a   Grall, Franck ^a   Delclaux, Christophe ^a   Losser, Marie Reine ^b   Heshmati, Fahrad ^a   Cheval, Christine ^c   Monchi, Mehran ^a   Teboul, Jean Louis ^d   Riché, Florence ^b   Leleu, Ghislaine ^e   Arbibe, Laurence ^a   Mignon, Alexandre ^a   Delpech, Marc ^f   Dhainaut, Jean François ^a  

^a Cochin Port Roy University Hospital ^*  (France)

^b Lyon University Hospital   (France)

^c Hospital Saint Joseph   (France)

^d BICÊTRE HOSPITAL   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DNA FRAGMENT; HLA ANTIGEN; HYPERTENSIVE FACTOR; LACTIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENATURING GRADIENT GEL ELECTROPHORESIS; DNA SEQUENCE; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; SEPTIC SHOCK;

EID: 0033546610     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.282.6.561     Document Type: Article

References (50)

1. Wenzel RP, Pinsky MR, Ulevitch RJ, Young L. Current understanding of sepsis. J Clin Infect Dis. 1996; 22:407-413.
2. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med. 1999;340:207-214.
3. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science. 1986;234:470-474.
4. Dinarello CA. Proinflammatory and antiinflammatory cytokines as mediators in the pathogenesis of septic shock. Chest. 1997;112(suppl 6): 321S-329S.
5. Mitchie HR, Manogue KR, Springgs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988;319: 1481-1486.
6. Girardin E, Grau GE, Dayer JM, et al, for the J5 Study Group: tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med. 1988;319:397-400.
7. Calandra T, Baumgartner JD, Grau GE, et al. Prognostic value of tumor necrosis factor-cachectin, interleukin-1, interferon-alpha and interferon-gamma in the serum of patients with septic shock. J Infect Dis. 1990;161:982-987.
8. Lynn WA, Cohen J. Adjunctive therapy for septic shock: a review of experimental approaches. Clin Infect Dis. 1995;20:143-158.
9. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. JAMA. 1995;273:934-941.
10. Cohen J, Carlet J, for the INTERSEPT Study Group. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis. Crit Care Med. 1996;24:1431-1440.
11. Abraham E, Anzueto A, Guttierez G, et al. Double-blind randomized controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet. 1998;351:929-933.
12. Molvig J, Baek L, Christensen P, et al. Endotoxin-stimulated human monocyte secretion of interleukin 1, tumour necrosis factor alpha and prostaglandin E2 shows stable interindividual differences. Scand J Immunol. 1988;27:705-716.
13. Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDewitt HO. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor α: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA. 1990;87:1233-1237.
14. Rink L, Kirchner H. Recent progress in the tumor necrosis factor-α field. Int Arch Allergy Immunol. 1996; 111:199-209.
15. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW. An allelic polymorphism within the human tumor necrosis factor-α promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med. 1993;177:557-560.
16. Wilson AG, Symons JA, McDowell TL, McDewitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor a promoter on transcriptional activation.Proc Natl Acad Sci USA. 1997;94:3195-3199.
17. Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-α promoter polymorphism effects transcription. Mol Immunol. 1997;34:391-399.
18. Warzocha K, Ribeiro P, Bienvenu J, et al. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood. 1998;91:3574-3581.
19. Louis E, Franchimont D, Piron A, et al. Tumor necrosis factor gene polymorphism influences TNF-alpha production in lipopolysaccharide-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol. 1998;113:401-406.
20. McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D. Variation of the TNF-α promoter region associated with susceptibility to cerebral malaria. Nature. 1994;371:508-510.
21. Nadel S, Newport MJ, Booy R, Levin M. Variation in the tumor necrosis factor-a gene promoter region may be associated with death from meningococcal disease. J Infect Dis. 1996;174:878-880.
22. Cabrera M, Shaw MA, Sharples C, et al. Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmanioasis. J Exp Med. 1995; 182:1259-1264.
23. Strüber F, Udalova IA, Book M, et al. -308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human promoter. J Inflamm. 1996;46:42-50.
24. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864-874.
25. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiologic Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270:2957-2963.
26. Knaus W, Draper E, Wagner D, et al. Multiple system organ failures: epidemiology and prognosis. Crit Care Med. 1989;5:221-232.
27. Myers RM, Fischer SG, Lerman LS, Maniatis T. Nearly all single base substitutions in DNA fragments joined to a GC-clamp can be detected by denaturating gradient gel electrophoresis. Nucleic Acids Res. 1985;13:3131-3145.
28. Costes B, Girodon E, Ghanem N, et al. Psoralen-modified oligonucleotide primers improve detection of mutations by denaturating gradient gel electrophoresis and provide an alternative to GC-clamping. Hum Mol Genet. 1993;2:393-397.
29. Gustafson S, Proper JA, Bowie EJW, Sommer SS. Parameters affecting the yield of DNA from human blood. Anal Biochem. 1987;165:294-299.
30. Wilson AG, di Giovine FS, Duff GW. Genetics of tumour necrosis factor-a in autoimmune, infectious and neoplastic diseases. J Inflamm. 1995;45:1-12.
31. Pociot F, D'Alfonso S, Compasso S, Scorza R, Richiardi PM. Functional analysis of a new polymorphism in the human TNF-α gene promoter. Scand J Immunol. 1995;42:501-505.
32. Vinasco J, Beraun Y, Nieto A, et al. Polymorphism at the TNF loci in rheumatoid arthritis. Tissue Antigens. 1997;49:74-78.
33. Hamann A, Mantzoros C, Vidal-Puig A, Flier JS. Genetic variability in the TNF-α promoter is not associated with type II diabetes mellitus. Biochem Biophys Res Com. 1995;211:833-839.
34. Colombani J. HLA Fonctions immunitaires et applications medicales. In: Libbey J, ed. Eurotext. 3rd ed. 1993:100-110.
35. Rogaeva E, Premkumar S, Song Y, et al. Evidence for an Alzheimer disease susceptibility locus on chromosome 12 and for further locus heterogeneity. JAMA. 1998;280:614-618.
36. Goldfed AE, Delgado JC, Thim S, et al. Association of an HLA-DQ allele with clinical tuberculosis. JAMA. 1998;279:226-228.
37. Iacoviello L, Di Castelnuovo A, De Knijff P, et al. Polymorphisms in the coagulation factor VII gene and risk of myocardial infarction. N Engl J Med. 1998;338: 79-85.
38. Lander ES, Schork NJ. Genetic dissection of complex traits. Science. 1994;265:2037-2048.
39. Verjans GM, Brinkman BMN, Van Doornik CEM, Kijlstra A. Polymorphism of tumor necrosis factor-alpha at position -308 in relation to ankylosing spondylitis. Clin Exp Immunol. 1994;97:45-47.
40. Conway DJ, Holland MJ, Bailey RL, et al. Scarring trachoma is associated with polymorphism in the tumor necrosis factor alpha gene promoter and with elevated TNF-a levels in tear fluid. Infect Immun. 1997; 65:1003-1006.
41. Dhainaut JF, Vincent JL, Richard C, et al. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. Crit Care Med. 1995; 23:1461-1469.
42. Aggarval BB, Natarajan K. Tumor necrosis factors: developments during the last decade. Eur Cytokine Netw. 1996;7:93-124.
43. Keel M, Ercknauer E, Stocker R, et al. Different pattern of local and systemic release of proinflammatory and antiinflammatory mediators in severely injured patients with chest trauma. J Trauma. 1996;40:907-912.
44. Andrejko KM, Deutschman CS. Acute-phase gene expression correlates with intrahepatic tumor necrosis factor alpha abundance but not with plasma tumor necrosis factor concentrations during sepsis/ systemic inflammatory response syndrome in the rat. Crit Care Med. 1996;24:1947-1952.
45. Pellegrini JD, Puyana JC, Lapchak PH, Kodys K, Millergraziano CL. A membrane TNF-alpha/TNFR ratio correlates to MODS score and mortality. Shock. 1996;6:389-396.
46. Bagby GJ, Plessala KJ, Wilson LA, Thompson JJ, Nelson S. Divergent efficiency of antibody to tumor necrosis factor-α in intravascular and peritonitis model of sepsis. J Infect Dis. 1991;163:83-88.
47. Wakabayashi G, Gelfand JA, Jung WK, Connolly RJ, Burke JF, Dinarello CA. Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia: comparison to Escherichia coli. J Clin Invest. 1991;87:1925-1935.
48. Bouma G, Crusius JBA, Oudkerk Pool M, et al. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles: relevance for inflammatory bowel disease. Scand J Immunol. 1996;43:456-463.
49. Hurme M, Lahdenpohja N, Santtila S. Gene polymorphisms of interleukins 1 and 10 in infectious and autoimmune diseases. Ann Med. 1998;30:469-473.
50. Bone RC. Why sepsis trials fail. JAMA. 1996;276: 565-566.